Maspin is a tumor and metastasis suppressor playing an essential role as gatekeeper of tumor progression. It is highly expressed in epithelial cells but is silenced in the onset of metastatic disease by epigenetic mechanisms. Reprogramming of Maspin epigenetic silencing offers a therapeutic potential to lock metastatic progression. Herein we have investigated the ability of the Artificial Transcription Factor 126 (ATF-126) designed to upregulate the Maspin promoter to inhibit tumor progression in pre-established breast tumors in immunodeficient mice. ATF-126 was transduced in the aggressive, mesenchymal-like and triple negative breast cancer line, MDA-MB-231. Induction of ATF expression in vivo by Doxycycline resulted in 50% reduction in tumor growth and totally abolished tumor cell colonization. Genome-wide transcriptional profiles of ATF-induced cells revealed a gene signature that was found over-represented in estrogen receptor positive (ER+) ''Normal-like'' intrinsic subtype of breast cancer and in poorly aggressive, ER+ luminal A breast cancer cell lines. The comparison transcriptional profiles of ATF-126 and Maspin cDNA defined an overlapping 19-gene signature, comprising novel targets downstream the Maspin signaling cascade. Our data suggest that Maspin up-regulates downstream tumor and metastasis suppressor genes that are silenced in breast cancers, and are normally expressed in the neural system, including CARNS1, SLC8A2 and DACT3. In addition, ATF-126 and Maspin cDNA induction led to the re-activation of tumor suppressive miRNAs also expressed in neural cells, such as miR-1 and miR-34, and to the down-regulation of potential oncogenic miRNAs, such as miR-10b, miR-124, and miR-363. As expected from its over-representation in ER+ tumors, the ATF-126-gene signature predicted favorable prognosis for breast cancer patients. Our results describe for the first time an ATF able to reduce tumor growth and metastatic colonization by epigenetic reactivation of a dormant, normal-like, and more differentiated gene program. 
Introduction
Mammary Serine Protease Inhibitor (Maspin, SERPINB5) is a multifunctional protein possessing tumor and metastasis suppressive functions [1, 2] . Additionally, Maspin over-expression inhibits in vivo angiogenesis [3] . The multifaceted nature of Maspin affecting many molecular mechanisms during neoplastic disease progression makes it a very attractive target in cancer biology. Importantly, clinical data shows that high Maspin levels are associated with better prognosis in breast, lung and prostate carcinomas [4, 5, 6] .
As a class II tumor suppressor gene, Maspin is not mutated, rearranged or deleted in tumor cells. Instead, its expression is regulated by means of transcription factors [7] and epigenetic modifiers [8, 9] . While Maspin is expressed at high levels by epithelial cells, it is down-regulated in mesenchymal cells, such as stromal fibroblasts. In breast cancer cell lines and cancer specimens, silencing of Maspin correlates with acquisition of invasive and metastatic behavior. Epigenetic mechanisms controlling Maspin silencing include both, DNA [9] and H3K9 histone methylation [10] . Hence epigenetic mechanisms are reversible yet inherited during cell division, blockade of Maspin promoter silencing offers a potent strategy to reactivate tumor suppressor function. To this end, we have previously described the construction of Artificial Transcription Factors (ATFs) made of sequence-specific six Zinc Finger (ZF) domains [11] designed to bind unique 18-base pair recognition sites in the Maspin proximal promoter [12] . The ZFs were linked to a VP64 transactivator domain, which mediates a strong promoter up-regulation by recruitment of the polII transcriptional complex. In cell systems, both in lung and breast cancer cell lines, retroviral transduction of one of the ATFs, ATF-126, led to a potent induction of apoptosis and inhibition of cell invasion [12, 13] . Furthermore, these ATFs were able to directionally demethylate the Maspin promoter and this effect depended on upon the orientation of the ATF along the DNA [13] . Consistently, we found that ATFs synergized with both methyltransferase and histone deacetylase inhibitors to reactivate silenced Maspin [13, 14, 15] . These previous observations suggested that ATF-126 was able to partially reprogram or revert the epigenetic state of the Maspin promoter, resulting in a re-activation of the endogenous gene. However, the impact of ATF-126 in inhibiting tumor progression in preexisting tumors and/or metastases in vivo has never been addressed. Herein, we have taken advantage of an inducible viral vector system to control the expression of ATF-126 in pre-existing breast tumor growths and experimental metastases in immunodeficient mice. Chemical induction of ATF-126 in vivo resulted in tumor suppression as well as in inhibition of breast tumor cell colonization. Furthermore, genome-wide DNA microarrays of MDA-MB-231 cells induced with ATF-126 revealed that breast tumor cells acquired a 550-gene signature that was found overrepresented in estrogen receptor positive (ER+) breast cancer cell lines and in the normal-like intrinsic subtype of breast cancer. Our data indicates that ATF-126 up-regulates novel Maspin-dependent targets possessing tumor and metastasis suppressive functions, which are found epigenetically silenced in aggressive tumors. Our results outline a possible mechanism by which ATF-126 reprograms aggressive tumor cells towards a more ''normal-like'', more benign, and more differentiated ''epithelial-like'' phenotype.
Results

Induction of ATF-126 by DOX results in endogenous reactivation of Maspin in MDA-MB-231 breast cancer cells
In order to monitor the effect of ATF-126 in inhibiting tumor progression in pre-existing tumors, we cloned the ATF-126 gene into an inducible TetOn retroviral vector (Fig. S1A) . In this expression system the ATF expression was activated only in presence of the chemical inducer, Doxycycline (DOX). The MDA-MB-231-LUC cell line stably engineered with a luciferase (LUC) gene was transduced with either a control (empty retroviral vector) or the same vector expressing ATF-126. The LUC gene allowed the non-invasive monitoring of tumor growth and dissemination in a mouse model, using bioluminescence imaging, BLI (Fig. S1B) .
The effects of inducing ATF-126 with DOX were first monitored in cell culture assays. As shown in Fig. 1A , induction of the full length ATF-126 (comprising the specific 6ZF DNAbinding domains and the VP64 transactivator domain) resulted in a dose-dependent ATF-126 expression, as assessed by qRT-PCR. The induction of the ATF was accompanied by a concomitant upregulation of the Maspin target (Fig. 1B) . For subsequent studies we used a concentration of DOX of 100 ng/ml at which the expression of both, ATF-126 and Maspin, reached saturation.
Efficient ATF-126 induction was also verified by immunoprecipitation (using an anti-HA antibody recognizing the C-terminal HA epitope of the ATF; Fig. 1C, left panel) . Maspin up-regulation in +DOX cells was also verified by immunoprecipitation (Fig. 1C , right panel). As shown in Fig. 1D , ATF-126 +DOX cells upregulated Maspin quickly after ATF-126 expression (6-12 hours after addition of DOX), as expected from direct transcriptional regulation. A saturation of ATF expression was reached 48 hours after the addition of the drug, whereas that Maspin up-regulation achieved a maximum at 72 hours post-induction (Fig. 1D) . Removal of DOX from the cell culture of ATF-126 cells also resulted in a decay of ATF expression that was evident 24 hours upon the retrieval of the drug. However, 72 hours after DOX removal, substantial Maspin expression was still detected in the cells even though ATF-126 mRNA expression was not. These results suggested that ATF-126 was able to transiently impact the epigenetic and transcriptional status of the Maspin promoter. Previously we have reported that ATF-126 was able to demethylate the Maspin proximal promoter [13] . Moreover, It is possible that the endogenous mechanisms responsible for Maspin silencing (including endogenous DNA-methylation processes) would be restored 96 hours after removal of DOX in ATF-126 transduced cells.
ATF up-regulation by DOX results in Maspin-dependent induction of apoptosis
Endogenous expression of tumor suppressors, including Maspin, has been associated with reduction of tumor cell viability by induction of apoptosis [12, 16] . Next, we studied if ATF-126 induction resulted in a reduction of tumor cell growth. As shown in Fig. 2A , the reactivation of ATF-126 (ATF-126 +DOX) led to 70% reduction in tumor cell viability relative to the same cells in absence of DOX (ATF-126 2DOX). As expected, no difference in cell viability was observed between CONTROL and ZF-126 (inactive ATF-126 lacking the activator domain) cells upon DOX induction. Interestingly, removal of DOX in ATF-126 cells led to a maintenance of the cell proliferation defect for 96 hrs after DOX removal (Fig. 2B) , and approximately over four cell generations. This maintenance of tumor suppression correlates with the time window of Maspin transcriptional activation of Fig. 1E . In addition to cell proliferation defects, ATF-126 +DOX cells exhibited a 40% induction of apoptosis, as assessed by Annexin-V staining, which monitors early apoptosis (Fig. 2C) . Similarly, 30-40% of ATF-126 +DOX cells were positive for the Hoechst staining, which labels apoptotic nuclei (Fig. 2D) .
To verify that the apoptotic response triggered by ATF-126 was due to Maspin reactivation, we challenged ATF-126 cells with either a Maspin-specific or scramble shRNA constructs. The Maspin-shRNA in ATF-126 +DOX cells led to a 60% reduction of Maspin mRNA expression (Fig. 2E) . As expected, a scramble shRNA construct did not significantly impact Maspin expression. Consistently, the scramble-shRNA in ATF-126 +DOX cells induced similar levels of cell death relative to the original ATF-126 +DOX cell line (Fig. 2F) . However, the Maspin-shRNA in ATF-126 +DOX cells was able to rescue the phenotype, and a significant reduction of cell death (55% of reduction) was observed in the Maspin knock-down relative to the scramble and the ATF-126 parental line +DOX (Fig. 2F) . Although the rescue of the cell death phenotype was not 100%, our results suggest that ATF-126 mediate reduction in tumor cell growth by primarily activation of its designed target Maspin. The incomplete rescue of the phenotype could be due the fact that the Maspin shRNA did not completely knocked down the mRNA transcript levels of Maspin, as shown in Fig. 2E . A siRNA approach further confirmed that the tumor suppressive phenotype observed in ATF-126 +DOX cells was due to Maspin re-activation. As shown in Figs. 2G-H, a Maspinspecific siRNA but not a non-specific mismatch (scramble) siRNA rescued the proliferation defect of ATF-126 +DOX cells. Overall these results support the conclusion that the cell death phenotype induced by ATF-126 was dependent on the Maspin target.
ATF-126 reduces xenograft tumor growth and suppresses metastatic colonization of MDA-MB-231 cells upon DOX induction in immunodeficient mice
To investigate the ability of ATF-126 to reduce tumor cell growth in pre-existing breast tumor xenografts, we implanted either control 1610 6 MDA-MB-231-LUC cells or ATF-126 cells in SCID mice (N = 8 animals per group). Animals were kept in DOX-free conditions until tumors reached 100-200 mm 3 ( Fig. 3A) . Eighteen days post-induction, half of the animals for control and ATF-126 groups were maintained in DOX-free diet, whereas the other half was switched to a +DOX diet. Tumor volume was assessed from the day before induction until tumor collection (day 41 post-injection), and BLI imaging was performed once a week. One of the animals belonging to the ATF-126 group previously induced with DOX was switched back to a DOX-free diet and sacrificed at day 53 post-injection (Fig. 3A) . As shown in Fig. 3B -C (left panels), no statistical differences in tumor growth were observed between CONTROL +DOX and -DOX animals. In contrast, ATF-126 animals induced with DOX exhibited a significant reduction of tumor volume (approximately 50% reduction) that was stably maintained until the mice were sacrificed at day 41 ( Fig. 3B-C, right panels) .
Interestingly, induced ATF-126 animals that were removed from DOX at day 41 experienced a tumor relapse (Fig. 3D) . This tumor recovery suggests that, like we have observed in vitro, longterm absence of ATF expression results in a re-establishment of Maspin silencing. Analysis of tumors recovered from the animals at day 41 demonstrated that the ATF-126 +DOX animals retained efficient ATF mRNA up-regulation (500-fold relative to uninduced animals). This induction of ATF mRNA was accompanied by a 20-fold Maspin up-regulation relative to 2DOX animals ( Fig. 3E) . Overall these results demonstrate that ATF-126 was properly up-regulated in the tumor xenograft experiment and that this induction correlated with Maspin reactivation and with the maintenance of tumor suppressive functions.
It is well documented for breast, prostate and lung carcinomas that high Maspin expression correlates with a less aggressive or metastatic behavior [17, 18, 19] . We next investigated the ability of ATF-126 to inhibit breast tumor colonization or experimental metastasis formation in immunodeficient mice. To address this, either 1610
5 MDA-MB-231-LUC CONTROL or ATF-126 cells were injected tail vein in SCID mice (N = 24). Twelve mice per group were maintained in DOX-free diet and 12 in +DOX diet. Because the need of the animals to adapt to a DOX diet, mice were feed three days prior to the injection (Fig. 4A) . Fig. 4B (top panel) shows that CONTROL +DOX and 2DOX cells effectively colonized the lungs and metastases were evident at day 14 post-injection. Similarly, the majority of the animals injected with ATF-126 maintained in DOX-free diet effectively colonized the lungs with similar signal intensities than CON-TROLS. In contrast, ATF-126 animals in +DOX diet completely suppressed experimental metastatic colonization at day 21 ( Fig. 4B, bottom panel) . Moreover, removal of DOX from the diet of ATF-126 animals maintained these mice free of any detectable lung colonization even 54 days post-injection (Fig. 4B , bottom right panel). Overall these results indicated that ATF-126 effectively suppressed metastatic colonization. Whether the ATF-126 is equally effective in suppressing or reducing secondary tumor growth in well-established macrometastases will require further investigation.
ATF-126 up-regulate a gene signature over-represented in the normal-like intrinsic subtype of breast cancer and ER+ cancer cell lines
The above results demonstrated that ATF-126 reduced tumor growth and suppressed metastatic colonization of the MDA-MB-231-LUC line. We next began the investigation of potential mechanisms by which ATF-126 could mediate its suppressive functions by performing genome-wide microarray analyses. CONTROL and ATF-126 cells where induced with DOX for 72 hours. Genes differentially regulated between 2DOX and +DOX groups were determined by SAM analyses, with three independent arrays performed for each group. These analyses generated a robust 550-gene signature, defined as group of genes differentially up-regulated by ATF-126 (see Table S1 ). A Gene Ontology (GO) analysis revealed that multiple Maspin downstream pathways were reactivated by ATF-126, including tight junction and cell invasion, TGF-beta, and p53 signaling (Table S2) .
We next examined this signature across intrinsic breast cancer subtypes, using the UNC337 tumor database comprising 337 breast tumor cases [20] . Our analysis shows that ATF-126 upregulated targets that are found over-represented in the ''Normallike'' intrinsic subtype of breast cancer (Fig. 5A) . Both Normal-like and Luminal A are ER+ tumors associated with the best prognosis of all breast tumor subtypes [21] . In contrast, the Basal-like and Claudin-low carcinomas are mostly triple negative breast cancers (ER-PR-Her2-) associated with high resistance to chemotherapy and poor prognosis [20] . Claudin-low tumors have been recently discovered through large-scale microarray analysis of breast cancer specimens [20, 22] . The MDA-MB-231 cell line used in this study was originally described as Basal B and has been recently characterized as Claudin-low [20, 21] . Our finding that ATF-126-responsive genes are enriched in ER+ ''Normal-like'', poorly aggressive tumors, correlates with the fact that ATF-126 induction in MDA-MB-231 confers a more benign, less tumorigenic phenotype. Consistent with this, we found that the ATF-126-upregulated gene signature was indicative or a predictor of a better prognosis in breast cancer patients (Fig. 5B) .
The relationship between the ATF-126-gene signature and ER status was further observed in available DNA-microarrays data of breast cancer cell lines [21] . Fig. 5C shows that the ATF-126-gene signature was found under-represented in Claudin-low and Basal-like ER-lines with the lowest enrichment found in the original MDA-MB-231 cell line. The same signature was overrepresented in luminal ER+ cell lines, including the poorly aggressive lines MCF-7 and ZR75. Overall our microarray analysis provides support that ATF-126 initiates a transcriptional gene program resulting in a reprogramming of the original ERaggressive Claudin-low MDA-MB-231 towards a less aggressive, and more ''normal-like'' breast cancer cell line. This is also consistent with the fact that high expression of Maspin, the primary target gene of ATF-126, is also associated with epithelial-like features [18] .
To dissect ''bona-fide'' downstream targets of Maspin in the 550-gene signature we cloned the Maspin cDNA into the same DOXinducible retroviral vector, and gene expression microarrays were performed in the Maspin cDNA 2DOX and +DOX transduced cell populations. 123 genes (Table S3) were found differentially up-regulated upon Maspin cDNA induction. Among these, 19 targets were shared with ATF-126 +DOX (Fig. 6A, Table 1 ). Nine of the most up-regulated Maspin-dependent candidate targets were further validated by qRT-PCR (Fig. 6B) . These genes included potential therapeutic targets normally expressed in the neural system, such as negative regulators of oncogenic signaling (the epigenetic regulator of Wnt/b-catenin signaling (DACT3) and the SRC kinase signaling inhibitor 1 (SRCIN1)), putative tumor suppressors in cancer (DACT3, SLC8A2, CARNS1, GNG4, END2), and the apoptosis-associated tyrosine kinase ATTK. Solute carrier family 8 (sodium/calcium exchanger), member 2 (SLC8A2), Carnosine synthase 1 (CARNS1), and Dapper, antagonist of beta-catenin, homolog 3 (DACT3) were up-regulated by more than 10-fold in both, ATF-126 and Maspin cDNA cells, and thus, could represent novel ''bona-fide'' Maspin-dependent targets.
We next took advantage of ATF-126 and Maspin cDNA inducible cell lines to examine whether oncogenic and tumor suppressive microRNAs were differentially regulated upon DOX induction. We analyzed the expression of 90 miRNAs often dysregulated in cancers, using a miRNA array platform by qRT-PCR. The expression of each miRNA was normalized to the MDA-MB-231 cell line. Interestingly, both, ATF-126 and Maspin cDNA, up-regulated miRNAs with potential tumor suppressive functions, such as miR-1 [23, 24] and miR-34 [25] , while downregulating oncogenes and metastasis promoters, including miR10b [26] (Fig. 6C) . In addition, we found that miR-124 which is required for somatic cells to reprogram to neural cells [27] , and miR-363 (Fig. 6C) , were down-regulated in both ATF-126 and Maspin cDNA. Thus, our target analysis suggests that ATF-126 Claudin-low carcinomas and representative cell lines are characterized by a down-regulation of epithelial junction proteins, such as cadherins and claudins [20] . Interestingly, multiple panels of epithelial markers, such as E-Cadherin (CDH1), Claudin 3 and 7, Ocludins, and keratins, were re-activated upon ATF-126 expression (Fig. 7A) . In addition, ATF-126 led to the generation of a CD24 positive population (Fig. 7B) . CD24 is expressed in many ER+ tumor cell lines, while its expression is absent in some basal and Claudin-low cell lines (Fig. S2) . CD44+/CD24-is considered a cancer stem cell or tumor initiating cell signature, and high CD44/CD24 ratios are characteristic of aggressive Claudin-low tumors and cell lines [20] . The reactivation of CD24 by ATF-126 suggests that ATF-126 could decrease the tumorigenic potential of MDA-MB-231 cells. In summary, the above results suggested that ATF-126 was able to initiate a transcriptional program resulting in a reprogramming of a more mesenchymal, Claudin-low phenotype, towards a more normallike, epithelial-like, and less aggressive breast tumor line (Fig. 7C) .
Discussion
In this paper we have investigated the ability of the ATF-126, designed to up-regulate Maspin, to decrease tumor growth and colonization of an aggressive MDA-MB-231 line. We found that induction of ATF expression in vivo resulted in 50% reduction in tumor growth. In addition, ATF expression abolished the capability of the breast cancer to colonize the lungs.
The approach used in this work facilitated the tight control of the ATF expression both in cell culture and in a breast cancer xenograft model. As a direct target of the ATF, we found that the Maspin transcript was induced with very similar time course kinetics than the ATF. Interestingly, removal of DOX from the cell culture media resulted in a quick decay of ATF-126 expression. However, we found that Maspin expression was still retained for at least four cell generations even in complete absence of ATF-126 mRNA expression. In the same time window of Maspin transcriptional activation, the ATF-126 +DOX cells maintained their proliferation defects, suggesting that the growth inhibition phenotype could be propagated for several cell generations upon DOX removal. The slow decay of Maspin expression and the maintenance of growth inhibition in absence of ATF expression could be the result of the modification of the epigenetic status of the Maspin promoter upon binding of the ATF. We have reported that two ATFs, ATF-126 and ATF-97, reduced DNA methylation levels in the Maspin promoter [13] . In addition, this demethylation effect was directional and depended upon de orientation of VP64 along the promoter. In this regard, it is possible that the slow Maspin decay in absence of ATF expression could reflect a time delay by which the endogenous epigenetic and/or transcriptional mechanisms restore Maspin silencing. To address this possibility, we are presently analyzing methylation patterns upon removal of DOX at different time points. Future engineering of ATFs should maximize this demethylation effect, thereby increasing the potency and therapeutic window of ATFs targeting tumor suppressor gene promoters. This unique engineering aspect of ATFs could facilitate the long-term, hereditary, and stable transmission of tumor suppression (''phenotypic Our results in vivo demonstrate that induction of ATF-126 in animal models led to a 50% reduction in breast cancer cell growth. Long-term removal of DOX from the diet of the animals resulted in a re-establishment of the tumors in vivo. As it was observed in our analysis in vitro, it is possible that long-term absence of ATF expression results in re-establishment of Maspin silencing. This is in contrast with our colonization model of breast cancer, in which removal of DOX from the ATF-126 induced animals did not result in a recurrence of metastasis. These results could be explained because most circulating tumor cells or cells that underwent an early colonization in the lungs were effectively targeted by the ATF. Nevertheless, we do not know at present if the ATF-126 will be also effective in suppressing well-established metastases and this will require further investigation.
In order to investigate potential downstream genetic signatures mediating the inhibition of tumor growth and colonization, we performed DNA arrays. Our genome-wide analysis revealed that ATF-126 up-regulated a 550-gene signature that was found overrepresented in the Normal-like intrinsic subtype of breast cancer, and as well as in luminal A breast cancer cell lines. Together with Luminal A, Normal-like breast cancers are associated with ER expression. These tumors are small, mostly found in postmenopausal women, tend to have normal p53 status, and are known to be genetically more stable than other tumor subtypes [17, 18] . Hence, Normal-like and Luminal A tumors both have a significant higher survival upon endocrine adjuvant therapy treatments after surgery as compared to other subtypes of breast cancers. As expected from its over-representation in Normal-like ER+ tumors, we found that the 550-gene signature predicted favorable prognosis for breast cancer patients.
In our cell line analysis, the 550-gene signature was underrepresented in the original MDA-MB-231 line as well as in ERbreast cancer lines, while it was highly over-represented in ER+ luminal lines. Although Normal-like cancer cell lines were absent in the cell line database of Neve et al. [21] it is highly possible that this signature will also be over-expressed in normal breast and (Table S1 ) This signature represents the number of genes significantly up-regulated in ATF-126 cells exposed to DOX for 72 hours relative to the same cells in absence of DOX. The prevalence of this signature was evaluated across the intrinsic molecular subtypes of breast cancers using the previously published UNC breast cancer patient database (UNC337). P values were calculated by comparing gene expression means across all breast tumor subtypes. B. Kaplan-Meier survival estimates of relapse-free survival for the Merge 550 database (left panel), relapse-free survival and overall survival for the NKI 295 database (center and right panel, respectively). Patients were stratified into group I (red curves) and group II (blue curves) based on 2-way hierarchy clusters. P-values were obtained from the log-rank test. C. Mean expression analysis of the ATF-126 gene signature across breast cancer cell lines [21] , showing the expression status of estrogen receptor (ER), Human Epidermal growth factor Receptor 2 (HER2) and progesterone receptor (PR). doi:10.1371/journal.pone.0024595.g005
Normal-like tumor cell lines. Consistent with this idea, we found that many junction proteins highly expressed in normal breast epithelial preparations, such as claudins, cadherins and ocludins, were induced upon DOX treatment. This reactivation of junction proteins suggests that ATF-126 was able to reprogram a highly invasive, Claudin-low, and mesenchymal breast cancer line towards a more Normal-like or epithelial-like, and less invasive cancer cell line. Furthermore, flow cytometric analysis of ATF-126 induced cells revealed a new CD24 positive population. Since the CD44 + /CD24 2 signature has been associated with tumor initiation, the up-regulation of CD24 population suggest that ATF-126 could decrease the tumor initiating ability of the original line MDA-MB-231.
The above phenotypic consequences of ATF-126 reactivation, inhibition of tumor growth and metastatic potential as well as gain of epithelial features, are all consistent with the documented functions of the target gene Maspin. The fact that both the Maspin shRNA and the Maspin siRNA were able to rescue the cell growth phenotype in ATF-126 transduced cells demonstrated that the phenotype of ATF-transduced cells was dependent on Maspin, and not on potential off target effects.
The molecular targets by which Maspin exerts its tumor/ metastasis suppressive functions are still under investigation. Maspin cDNA over-expression results in re-activation of multiple pathways involved in tumor suppression and apoptosis, motility, and cell adhesion [18] , [16] . In agreement with these functions of Maspin, we have found that tight junction, cell adhesion, and multiple tumor suppressive pathways were activated by ATF-126.
To dissect the downstream targets of ATF-126 that were ''bona fide'' downstream targets of Maspin, the Maspin cDNA was cloned into the same inducible retroviral vector, and genome-wide transcriptional profiles were compared between the un-induced and induced cells. An overlapping 19-target gene signature between the ATF-126 and the Maspin cDNA expressing cells was built, which represents ''high confidence'' hits by which Maspin could exert its mechanism of function in Claudin-low breast cancer cells. It is important to note that ATF-126 and Maspin cDNA represent two different mechanisms to up-regulate target gene expression; whereas the Maspin cDNA over-expresses the exogenous transgene form of Maspin, the ATF reactivates the endogenous gene, which results in up-regulation the physiologically relevant isoform, at ''normal'' cellular levels. In addition, unlike cDNA over-expression, which is predominantly cytoplasmic, the ATF-126 also results in substantial activation of the nuclear form of Maspin (manuscript in preparation), which mediates tumor and metastasis suppressive functions [28] . Thus, it is not surprising that transcriptional profiles of ATF-126 and Maspin cDNA were overlapping, yet not identical. Definitive analysis of genome-wide binding specificity of ATF-126 will require the integration of ChIP-seq data, which is underway. Overall, our results outlined the importance of using several methodologies to up-regulate Maspin, which allowed the dissection of potential therapeutic targets downstream the Maspin cascade.
Three targets belonging to this overlapping 19-gene signature were up-regulated by 10-100 fold over un-induced cells: Solute carrier family 8 (sodium/calcium exchanger), member 2 (SLC8A2), Carnosine synthase 1 (CARNS1), and Dapper, antagonist of beta-catenin, homolog 3 (DACT3). These genes represent novel Maspin targets with potential tumor suppressor activity. SLC8A2 encodes a Na(+)/ Ca(2+) exchanger, participating in intracellular Ca(2+) homeostasis, and its expression is restricted to the brain. Interestingly, SLC8A2 is found silenced by methylation in human gliomas where it has been proposed to act a tumor suppressor gene [29] . CARNS1 belongs to the ATP-grasp family of ATPases, and catalyzes the formation of carnosine (beta-alanyl-L-histidine) and homocarnosine (gamma-aminobutyryl-L-histidine). Carnosine is a naturally occurring substance discovered more than a hundred years ago, and is present in the mammalian brain and skeletal muscle [30] . Although is function is still under investigation, Carnosine has been proposed to have a protective effect against oxidative stress and represents a potential therapeutic agent for treatment of aging and Alzheimer's disease [31] . More recently Carnosine has been shown to inhibit proliferation of human brain cancer cells in vitro [32] . In 2010 a report showed that Carnosine retarded tumor growth in vivo in a NIH3T3-HER2/neu mouse model [33] . Thus, our results suggest that CARNS1 could potentially represent a Maspin-dependent tumor suppressor enzyme in Claudin-low carcinomas. DACT3 is expressed in the embryonic CNS, and is a negative regulator of Wnt/b-catenin signaling [34] . DACT3 is down-regulated in colorectal cancers by epigenetic mechanisms including histone methylation and deacetylation [35] . Given the importance of Wnt/b-catenin in the mammary gland tumorigenesis in triple negative, mesenchymal breast cancers [36] , we speculate that DACT3 represents a potential therapeutic target for these carcinomas.
ATF-126 and in less extent Maspin cDNA +DOX cells upregulated the protein gamma-4 subunit/guanine nucleotide-binding protein 4 (GNG4) gene, a brain-specific protein [37] with potential tumor suppressor activity, which, like Maspin [38] , is up-regulated by hypoxia factors [39] . Another unexplored potential target of Maspin in the 19-gene signature is the Apoptosis-Associated Tyrosine kinase (AATYK), a protein kinase predominantly expressed in the nervous system. AATYK regulates apoptosis, neurite growth, and differentiation of cerebellar granule cultures [40] . Lastly, ATF-126, and in less extent Maspin cDNA, up-regulated the SRC kinase signaling inhibitor 1 (SRCIN1), a gene encoding a novel Src-binding protein that regulates Src activation. Gain and loss of function approaches in breast and colon cancer cells demonstrated that SRCIN1 inhibits EGFR and Erk1/2 signaling, blocking scatter and proliferation of cancer cells [41] . In neurons, SRCIN1 is predominantly localized to dendritic spines and enriched in the postsynaptic density, where it modulates spine shape via regulation of the actin cytoskeleton [42] .
In addition to potential tumor/metastasis suppressor ORFs naturally expressed in neural cells, both ATF-126 and Maspin cDNA up-regulated miRNAs previously associated with tumor suppression in many types of cancers, including miR-1 [23, 24] and miR-34 [25] . Intriguingly again, miR-1 is naturally expressed in dorsal root ganglion neurons where it has a role in modulating neurite outgrowth [43] . Similarly, miR-34 has been shown to target Actin in mouse neuronal cells [44] . In addition to activation of potential tumor suppressive miRNAs, both ATF-126 and Maspin cDNA down-regulated putative oncogenes, including miRNA-10b.
The up-regulation of epigenetically silenced genes and miRNAs normally expressed in the nervous system is intriguing. Once overexpressed in tumors, these targets could be involved in differentiation of tumor cells, and metastasis inhibition. As a member of the SERPIN gene superfamily, nuclear Maspin is physically associated with Histone Deacetylase 1 (HDAC1) and functions as an HDAC inhibitor, remodeling chromatin and mediating gene reactivation [28, 45] . This is in agreement with our data, and could mechanistically explain the epigenetic reactivation of multiple tumor suppressors epigenetically silenced in poorly differentiated tumor cells, and the overall reprogramming of a mesenchymal line towards a more benign, more differentiated, and less aggressive cell line. Subsequent analysis in our identified Maspin targets will reveal whether Maspin directly binds the promoter of these genes, resulting in tumor and metastasis suppression. We are presently addressing the potential of ATFs to be delivered in breast tumors and metastasis, using nanoparticle-based strategies (manuscript in preparation). Another line of investigation will ascertain if ATFs can increase the sensitivity of ER-tumors to anti-cancer drugs used in the clinic, such as anti-estrogens.
Materials and Methods
Cell lines
The human breast cancer cell line MDA-MB-231 (ATCC, Cat. No. HTB-26) and all stable cell lines derived from it were cultured in DMEM medium supplemented with 10% fetal bovine serum and grown at 37uC in a humidified 5% CO 2 incubator.
Development of a double stable Tet-On cell lines
The ZF-126, the ATF-126, and the Maspin cDNA were cloned into the p-RetroX-Tight (Cat. Num. 632104, CloneTech, Moun- tain View, CA, US), and delivered into the MDA-MB-231-LUC cells by retroviral transduction. After transduction the cells were placed under selection with puromycin (1 mg/ml) and geneticin (800 mg/ml) for ten days. The CONTROL (p-RetoX-Tight empty vector), ZF-126 (p-RetoX-Tight-ZF-126), the ATF-126 (p-RetoXTight-ATF-126), and the Maspin cDNA (p-RetoX-Tight-Maspin) stable cell lines were expanded and used for in vitro and in vivo experiments.
ShRNA stable cell lines
Scramble and Maspin shRNAs (Open Biosystems) were cotransfected with pMDG.1 into 293TGag-Pol cells to produce retroviral particles. Transfection was done using Lipofectamine system. The viral supernatant was used to infect the MDA-MB-231-ATF-126 stable cell line. Cells were treated with hygromycin B (100 mg/ml) for 10 days.
siRNA Maspin gene knock-down
The p-RetoX-Tight-ATF-126 stable cell line was reversetransfected with either 50 nM of Maspin siRNA smart pool (4 siRNAs/pool) or mismatch siRNA, and complexed with dharma-FECT reagent (all siRNAs and reagents from Dharmacon, Chicago, IL, USA). Transfection conditions were optimized using a cytotoxic siRNA targeted against human ubiquitin B (Dharmacon). Cells were induced with DOX for 24 hours, then 2.5610 5 cells/well were transfected in 6-well plates, and DOX was added. Cells were maintained in transfection media for 72 hours, and subjected qRT-PCR analysis.
Gene expression, western blot, proliferation, Immunofluorescence and apoptosis assays were performed as described [13] . Primers and probes for gene expression assays are shown in Table  S4 . Primary and secondary antibodies from the corresponding companies were applied at the concentrations shown in Table S5 .
Quantification of cell death
Cells were collected and centrifuged 5 min at 1006g, then resuspended in 0.2% trypan blue. Cells were incubated 3 min at room temperature and counted on a hemacytometer. The percentage of cell death was calculated by comparing all samples counts with the ATF-126 2DOX cells.
Subcutaneous Injections
Female SCID mice (age 4 weeks) were purchased from Taconic Farms and housed under pathogen-free conditions. The Institu- tional Animal Care and Used Committee (IACUC) at the University of North Carolina at Chapel Hill approved all experiments described herein. MDA-MB-231-Control-LUC or MDA-MB-231-ATF126-LUC cells (1610 6 ) were collected and resuspended with matrigel (BD Bioscience, San Diego, CA, US) 1:1 volume ratio in a total volume of 100 ml. The cell-matrigel mixture was injected into the mouse flank. Tumor growth was monitored by caliper twice a week. When the tumor reached a size of approximately 0.5 cm, doxycycline (+DOX) was administered to mice in form of green food pellet (200 mg/Kg of mice chow) for a period of 25 days. For the DOX removal group, the DOX food was replaced by normal food. During the entire experiment the mice weight was monitored to verify whether toxicity occurred. After DOX treatment, the tumor volume was monitored both by caliper and Bioluminescence imaging (BLI) as described [13] . Assessment of tumor shrinkage was monitored one day previous to DOX induction and the day of tumor collection.
Tail-vein
Three days before the injections mice were kept in normal or DOX+ diet. Animals were injected via tail-vein with either 1610 5 MDA-MB-231-Control-LUC or MDA-MB-231-ATF126-LUC cells in 100 ml of PBS. BLI imaging was performed as described [13] . Assessment of tumor growth was monitored in vivo once a week for up to 8 weeks.
Flow cytometry
Cells were stained with primary antibodies anti-CD24-conjugated with phycoerythrin (PE) and anti-CD44 conjugated with Fluorescein isothiocyanate (FITC) (BD Bioscience, San Diego, CA, US) following the manufacturer's recommendations. Analysis was performed using a FACScalibur flow cytometer and the CellQuestTM software.
Gene expression microarrays
A total of six cell lines were used for gene expression analyses: CONTROL 2DOX, CONTROL +DOX, ATF-126 2DOX, ATF-126 +DOX (all with 3 technical replicates), p-RetoX-TightMaspin 2DOX, and p-RetoX-Tight-Maspin +DOX (with 2 technical replicates). For each cell line, total RNA was purified, amplified, labeled, and hybridized [46] using Agilent Agilent 4644 K oligo microarrays (Agilent Technologies, United States). All microarray data is available in the Gene Expression Omnibus (GEO) Database (http://www.ncbi.nlm.nih.gov/geo/query/acc. cgi?token = nnolvkqsosuwwlm&acc = GSE27842). The probes/ genes were filtered by requiring the lowest normalized intensity values in both 2DOX and +DOX samples to be .10. The normalized log2 ratios (Cy5 sample/Cy3 control) of probes mapping to the same gene were averaged to generate independent expression estimates. We also used available microarrays from the breast cancer cell lines [21] , the UNC337-patient [20] , the MERGE 550-patient dataset [47] and the NKI (295 patients [48, 49] ). All microarray cluster analyses were displayed using Java Treeview version 1.1.3. Average-linkage hierarchical clustering was performed using Cluster v2.12 [50] . ANOVA tests for gene expression data were performed using R (http://cran.r-project. org).
ATF-126/Maspin cDNA gene signatures
In order to build an ATF-126 signature, we selected those genes that were significantly differentially expressed between ATF-126+DOX and ATF-126 2DOX using SAM, with ,1% FDR. The resulting up-regulated gene list is shown in Table S1 .
In order to determine the genes up-regulated with the Maspin cDNA, two biological replicates of the non-induced cells (2DOX) and cells induced with DOX were subjected to DNA microarray analyses, as described above. Gene expression values from the Maspin cDNA 2DOX (N = 2) was subtracted from the Maspin cDNA +DOX (N = 2), and the 132 up-regulated genes are shown in Table S5 .
MicroRNA microarrays
Total RNA was purified from the ATF-126 and the Maspin cDNA cells treated with either vehicle (2DOX) or DOX for 72 hours using Trizol. Small RNAs were enriched using the miRNeasy Mini Kit (SA Biosciences, Frederick, MD, USA), and cDNA was generated with the RT2 miRNA First Strand Kit (SABiosciences, Frederick, MD, USA). Samples were subjected to MAH-102-C Micro-RNA arrays (SABiosciences, Frederick, MD, USA), and data was normalized to the vehicle treated cells (2DOX). Expression of miR-10b, miR-1, miR-34a, miR363, and miR-124 was validated in two independent assays using hydrolysis probes ( Table S4 ).
Prediction of relapse-free survival (RFS)
To determine if the 550-gene signature was represented in cancer patients from whom clinical data was available, we used two patient data sets: the NKI-295 and the MERGE-550. First, we examined the expression of the 550 genes in the MERGE-550 database and found that 322 out of the 550 genes were detected. A 2-way hierarchy cluster stratified the 322 patients into 2 groups (cluster I and cluster II; Fig. S3 ). Patients in cluster II had a significant better relapse free survival outcome (in 7 years followup) than patients in cluster I. Second, we repeated the analysis using the NKI dataset and found 444 genes. A 2-way hierarchy cluster stratified the 295 patients into 2 groups (cluster I and cluster II; Fig. S4 ). Here again, patients in cluster II had a significant improved relapse free survival outcome and overall survival outcome (in 18 years follow-up) relative to patients in cluster I. stratified the 550 patients into two groups (cluster I and cluster II); patients in cluster II had a significant better relapse free survival outcome (in 7 years follow-up) than patients in cluster I. Each colored square on the upper right represents the relative mean transcript abundance (in log2 space) with highest expression being red, average expression being black, and lowest expression being green. (TIFF) Figure S4 Gene clustering showing the 444 genes from the ATF-126-550 gene signature present in the NKI-295 patient dataset. Two-way hierarchy cluster stratified the 295 patients into 2 groups (cluster I and cluster II); patients in cluster II had a significant better relapse free survival outcome and overall survival outcome (in 18 years follow-up) than patients in cluster I. Each colored square on the upper right represents the relative mean transcript abundance (in log2 space) with highest expression being red, average expression being black, and lowest expression being green. (TIFF) 
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